

Strategic Collaboration with Amgen

Presentation for teleconference and webcast

October 4, 2016


- Nuevolution business model
- Deal and deal terms of the strategic collaboration with Amgen
- Profile of Amgen

Partners

Revenues/
Deal structure

Risks
Science Business

Discovery/pre-clinical deals (avg.)*



Risk-sharing/
Pre-sale collab.

Ongoing
discussions

Yes

"No"

Program licensing

Ongoing
negotiations

Yes

Yes

- Program licensing and Risk-sharing/Pre-sale collaboration create significant value for our shareholders
- In Risk-sharing/Pre-sale collaborations, the business risk is mitigated and development costs are lowered

Responsibilities

- Nuevolution responsible for early research phase
- Amgen and Nuevolution will collaborate during late-stage research
- Amgen is fully responsible for pre-clinical and clinical development as well as global commercialization

Synergistic combining of Nuevolution's and Amgen's strongholds

- Leveraging Nuevolution's powerful Chemetics drug discovery platform
- Leveraging Amgen's disease expertise in oncology and neuroscience, and development capabilities

Payments up to USD 410 million per program and tiered royalties


- Amgen has an *exclusive option* to obtain all rights to successfully developed programs
- Nuevolution is eligible to receive payments up to USD 410 million per target:
 - *license fee payment* upon Amgen's option exercise and
 - *milestone payments* upon achievement of specified R&D and commercial milestones as well as
 - *tiered royalties* on future sales

AMGEN®

- No. 11 on 2015 global prescription drug sales*
- USD 20.9bn in 2015 product sales
- Among the fastest growing top-15 drug majors

- Top-3 position in oncology**
- Key oncology drugs: Neulasta, Neupogen, Aranesp, Epogen, Vectibix, Kyprolis, Blincyto, Imlygic

- ✓ • During the IPO roadshow in November 2015, we announced expectations for 1-2 risk-sharing and 1-2 program licensing agreements within 12-18 months
 - First deal achieved in 11 months
- ✓ • Nuevolution-Amgen collaboration agreement fits Nuevolution's business model focused on creating shareholder value
- ✓ • The strategic collaboration with Amgen is Nuevolution's 16th deal to date
- ✓ • Payments up to USD 410 million per target plus tiered royalties on future sales



NUEVOLUTION

TRANSFORMING CHALLENGES
INTO MEDICINE